Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase II drugs for Thyroid Cancer have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Famitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Famitinib overview

Famitinib (SHR-1020) is under development for the treatment of solid tumors such as recurrent or metastatic cervical cancer, metastatic differentiated thyroid carcinoma including papillary thyroid carcinoma, celiac fibromatosis associated with familial adenomatous polyposis, anaplastic thyroid cancer, esophageal squamous cell carcinoma, thyroid follicular carcinoma and undifferentiated thyroid carcinoma, metastatic medullary thyroid carcinoma and undifferentiated thyroid carcinoma, intrahepatic cholangiocarcinoma, colorectal adenocarcinoma, unresectable urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra, osteosarcoma and gastrointestinal stromal tumor. It is administered through oral route as capsule and tablet. SHR-1020 is a tyrosine-inhibitor agent. The drug candidate act by targeting stem-cell factor receptor (c-Kit), vascular endothelial growth factor receptor (VEGFR2), fibroblast growth factor receptors (FGFR), platelet-derived growth factor (PDGFR), vascular endothelial growth factor receptor VEGFR3, Fms-like tyrosine kinases (Flt1 and Flt3). It was also under development for recurrent and metastatic nasopharyngeal carcinoma (NPC), HER2-negative metastatic breast cancer, metastatic renal cell carcinoma, non-squamous non-small cell lung cancer and gastroentero pancreatic neuroendocrine tumor.

It was under development for the treatment of gastrointestinal stromal tumor and idiopathic pulmonary fibrosis, metastatic colorectal cancer.

Jiangsu Hengrui Medicine overview

Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.

For a complete picture of Famitinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.